Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
K B Rohr
Observed names:
K Rohr,
K.B. Rohr,
KB Rohr
Institution:
Boehringer Ingelheim (Germany)
Observed institution:
Boehringer Ingelheim (Germany)
OpenAlex ID:
A5110932571
Acute Exacerbations in Patients with Progressive Fibrosing Interstitial Lung Diseases: Data from the INBUILD Trial
2022
·
M. Kreuter
, E. Bendstrup
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
4
Effects of nintedanib on dyspnoe, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial*
2021
·
M Kreuter
, J J Swigris
, et al.
·
Pneumologie
·
1
Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs)
2021
·
F Bonella
, T M Maher
, et al.
·
Pneumologie
·
1
C103-24 Effect of Nerandomilast in Patients With Progressive Pulmonary Fibrosis (PPF) by Gap Stage: Subgroup Analysis of the FIBRONEER-ILD Trial
2026
·
A Podolanczuk
, M Kuwana
, et al.
·
American Journal of Respiratory and Critical Care Medicine
Acute Exacerbations in Patients with Progressive Fibrosing Interstitial Lung Diseases: Data from the INBUILD Trial*
2023
·
M Kreuter
, E Bendstrup
, et al.
·
Pneumologie
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
2022
·
W A Wuyts
, F Bonella
, et al.
·
European Respiratory Journal
Effect of nintedanib on decline in forced vital capacity (FVC) in patients with progressive fibrosing interstitial lung diseases (ILDs) by time since diagnosis*
2022
·
D Skowasch
, M Strek
, et al.
·
Pneumologie
Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD trial*
2022
·
D Koschel
, C Kelly
, et al.
·
Pneumologie
Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?*
2022
·
S Gläser
, M S Wijsenbeek
, et al.
·
Pneumologie
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON*
2022
·
F Bonella
, W A Wuyts
, et al.
·
Pneumologie
Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial*
2022
·
M Kreuter
, T M Maher
, et al.
·
Pneumologie
Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by Time Since Diagnosis
2021
·
M.E. Strek
, R.W. Hallowell
, et al.
·
American Journal of Respiratory and Critical Care Medicine
PDF
Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by GAP Stage
2021
·
C.J. Ryerson
, N. Chaudhuri
, et al.
·
American Journal of Respiratory and Critical Care Medicine
PDF
PRS1 Systematic Literature Review of Treatments for Interstitial Lung Disease in Patients with a Progressive Fibrosing Phenotype
2020
·
K.B. Rohr
, M. Baldwin
, et al.
·
Value in Health
Correlation between home and clinic spirometry in subjects with IPF: results from the INMARK trial*
2020
·
D Koschel
, TM Maher
, et al.
·
Pneumologie
Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial*
2020
·
A Prasse
, TM Maher
, et al.
·
Pneumologie
Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study*
2020
·
M Pfeifer
, TM Maher
, et al.
·
Pneumologie
Show more works
View as search
Works count:
17
Citation count:
6
H-index:
1
I10-index:
Year
Topic
Type
